AQR Arbitrage’s NRX Pharmaceuticals NRXP Stock Holding History

AQR Arbitrage’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-20,000	Closed	-$2.12M	–	582
2019 Q4	$2.12M	Hold	20,000	–	–	0.04%	256
2019 Q3	$2.09M	Hold	20,000	–	–	0.03%	241
2019 Q2	$2.09M	Hold	20,000	–	–	0.02%	257
2019 Q1	$2.06M	Hold	20,000	–	–	0.03%	234
2018 Q4	$2M	Hold	20,000	–	–	0.03%	228
2018 Q3	$2M	Hold	20,000	–	–	0.02%	242
2018 Q2	$1.98M	Hold	20,000	–	–	0.02%	226
2018 Q1	$1.95M	Hold	20,000	–	–	0.02%	204
2017 Q4	$1.94M	Buy	+20,000	New	+$1.93M	0.02%	199

Other funds holding NRXP

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 51.47% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BCM

Bluefin Capital Management New York $156M AUM 18.42% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

AQR Arbitrage's NRXP Position: Q1 2020 in Review

AQR Arbitrage sold out of NRX Pharmaceuticals (NRXP) in Q1 2020, closing a stake of 20,000 shares — an estimated $2.12M sold.

AQR Arbitrage first reported a position in NRXP in Q4 2017 and held it in 9 quarters. The position peaked at $2.12M in Q4 2019. 7 funds tracked by Wall St. Rank hold NRXP as of Q1 2020.

AQR Arbitrage reported no remaining NRX Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
AQR Arbitrage sold 20,000 NRX Pharmaceuticals shares in Q1 2020, an estimated $2.12M.
AQR Arbitrage first reported a position in NRX Pharmaceuticals in Q4 2017 and held it in 9 quarters.
AQR Arbitrage's NRX Pharmaceuticals position peaked at $2.12M in Q4 2019.
7 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2020.

Based on AQR Arbitrage's 13F filing for Q1 2020, filed 15 May 2020.